Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis

Overview

Journal J Addict Med

Specialty Psychiatry

Date 2022 Jun 2

PMID 35653782

Authors

Anees Bahji

Paxton Bach

Marlon Danilewitz

David Crockford

Daniel J Devoe

Nady El-Guebaly

Richard Saitz

Affiliations

Soon will be listed here.

Abstract

Background: We aimed to determine medications' comparative efficacy and safety for adults with alcohol use disorders.

Methods: We searched eleven electronic data sources for randomized clinical trials with at least 4 weeks of treatment reporting on alcohol consumption (total abstinence and reduced heavy drinking), dropouts, and dropouts due to adverse events. We conducted network meta-analyses using random-effects, frequentist models, and calculated summary rate ratios (RRs) with 95% confidence intervals (CIs).

Results: We included 156 trials (N = 27,334). Nefazodone (RR = 2.11; 95% CI, 1.42-3.13), aripiprazole (RR = 1.97; 95% CI, 1.36-2.88), carbamazepine (RR = 1.85; 95% CI, 1.03-3.32), and nalmefene (RR = 1.17; 95% CI, 1.01-1.35) were associated with the most dropouts. Baclofen (RR = 0.83; 95% CI, 0.70-0.97) and pregabalin (RR = 0.63; 95% CI, 0.43-0.94) caused fewer dropouts than placebo. Nalmefene (RR = 3.26; 95% CI, 2.34-4.55), fluvoxamine (RR = 3.08; 95% CI, 1.59-5.94), and topiramate (RR=2.18; 95% CI, 1.36-3.51) caused more dropouts from adverse events over placebo. Gamma-hydroxy-butyrate (RR = 1.90; 95% CI, 1.03-3.53), baclofen (RR = 1.80; 95% CI, 1.39-2.34), disulfiram (RR = 1.71; 95% CI, 1.39-2.10), gabapentin (RR = 1.66; 95% CI, 1.04-2.67), acamprosate (RR = 1.33; 95% CI, 1.15-1.54), and oral naltrexone (RR = 1.15; 95% CI, 1.01-1.32) improved total abstinence over placebo (Fig. 3C). For reduced heavy drinking, disulfiram (RR = 0.19; 95% CI, 0.10-0.35), baclofen (RR = 0.72; 95% CI, 0.57-0.91), acamprosate (RR = 0.78; 95% CI, 0.70-0.86), and oral naltrexone (RR = 0.81; 95% CI, 0.73-0.90) were efficacious against placebo.

Conclusions: The current meta-analyses provide evidence that several medications for AUDs are effective and safe and encourage the expanded use of these medications in the clinical setting. Our review found that acamprosate (2-3 g/d), disulfiram (250-500 mg/d), baclofen (30 mg/d), and oral naltrexone (50 mg/d) had the best evidence for improving abstinence and heavy drinking for patients with AUD.

Prospero: CRD42020208946.

Citing Articles

Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies.

Huang D, Yao Y, Lou Y, Kou L, Yao Q, Chen R Int J Pharm X. 2024; 8:100307.

PMID: 39678262 PMC: 11638648. DOI: 10.1016/j.ijpx.2024.100307.

Psychedelic Research for Alcohol Use Disorder with Comorbid Major Depressive Disorder: An Unmet Need.

de Jonge D, van der Meer P, Kramers C, Schellekens A Curr Psychiatry Rep. 2024; 26(12):832-842.

PMID: 39612154 DOI: 10.1007/s11920-024-01567-4.

Posttraumatic Stress Disorder and Substance Use Disorder Screening, Assessment, and Treatment.

Patton S, Watkins L, Killeen T, Hien D Curr Psychiatry Rep. 2024; 26(12):843-851.

PMID: 39407067 DOI: 10.1007/s11920-024-01547-8.

[Patient and quality characteristics in the treatment with disulfiram (Antabus) in the German "Network for Alcohol Aversive Pharmacotherapy"].

Zimmermann U, Plickert C, Ludecke C, Stuppe M, Rosenbeiger C, Krisam Y Nervenarzt. 2024; 96(2):159-165.

PMID: 39172252 PMC: 11876189. DOI: 10.1007/s00115-024-01714-5.

Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.

Mansson A, Danielsson A, Sjoqvist H, Glatz T, Lundin A, Wallhed Finn S Addict Sci Clin Pract. 2024; 19(1):41.

PMID: 38764075 PMC: 11103816. DOI: 10.1186/s13722-024-00471-9.

References

Hartung D, McCarty D, Fu R, Wiest K, Chalk M, Gastfriend D . Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies. J Subst Abuse Treat. 2014; 47(2):113-21. PMC: 4110954. DOI: 10.1016/j.jsat.2014.03.007. View

Rosner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M . Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010; (12):CD001867. DOI: 10.1002/14651858.CD001867.pub3. View

Palpacuer C, Duprez R, Huneau A, Locher C, Boussageon R, Laviolle B . Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate. Addiction. 2017; 113(2):220-237. DOI: 10.1111/add.13974. View

Kranzler H, Tennen H, Armeli S, Chan G, Covault J, Arias A . Targeted naltrexone for problem drinkers. J Clin Psychopharmacol. 2009; 29(4):350-7. PMC: 3184851. DOI: 10.1097/JCP.0b013e3181ac5213. View

Hutton B, Salanti G, Caldwell D, Chaimani A, Schmid C, Cameron C . The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015; 162(11):777-84. DOI: 10.7326/M14-2385. View

Leung J, Hall-Flavin D, Nelson S, Schmidt K, Schak K . The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015; 49(8):897-906. DOI: 10.1177/1060028015585849. View

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

Spithoff S, Turner S, Gomes T, Martins D, Singh S . First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. Can Fam Physician. 2017; 63(5):e277-e283. PMC: 5429069. View

Suh J, Pettinati H, Kampman K, OBrien C . The status of disulfiram: a half of a century later. J Clin Psychopharmacol. 2006; 26(3):290-302. DOI: 10.1097/01.jcp.0000222512.25649.08. View

10.

Falk D, Ryan M, Fertig J, Devine E, Cruz R, Brown E . Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety. Alcohol Clin Exp Res. 2018; 43(1):158-169. PMC: 6317996. DOI: 10.1111/acer.13917. View

11.

Reus V, Fochtmann L, Bukstein O, Eyler A, Hilty D, Horvitz-Lennon M . The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018; 175(1):86-90. DOI: 10.1176/appi.ajp.2017.1750101. View

12.

Al-Otaiba Z, Worden B, McCrady B, Epstein E . Accounting for self-selected drinking goals in the assessment of treatment outcome. Psychol Addict Behav. 2008; 22(3):439-43. PMC: 3573699. DOI: 10.1037/0893-164X.22.3.439. View

13.

Barrio P, Gual A . Patient-centered care interventions for the management of alcohol use disorders: a systematic review of randomized controlled trials. Patient Prefer Adherence. 2016; 10:1823-1845. PMC: 5029836. DOI: 10.2147/PPA.S109641. View

14.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

15.

Kranzler H, Feinn R, Morris P, Hartwell E . A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. Addiction. 2019; 114(9):1547-1555. PMC: 6682454. DOI: 10.1111/add.14655. View

16.

Skinner M, Lahmek P, Pham H, Aubin H . Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014; 9(2):e87366. PMC: 3919718. DOI: 10.1371/journal.pone.0087366. View

17.

Dawes M, Johnson B . Pharmacotherapeutic trials in adolescent alcohol use disorders: opportunities and challenges. Alcohol Alcohol. 2004; 39(3):166-77. DOI: 10.1093/alcalc/agh045. View

18.

Rouse B, Chaimani A, Li T . Network meta-analysis: an introduction for clinicians. Intern Emerg Med. 2016; 12(1):103-111. PMC: 5247317. DOI: 10.1007/s11739-016-1583-7. View

19.

Guyatt G, Oxman A, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336(7650):924-6. PMC: 2335261. DOI: 10.1136/bmj.39489.470347.AD. View

20.

Pani P, Trogu E, Pacini M, Maremmani I . Anticonvulsants for alcohol dependence. Cochrane Database Syst Rev. 2014; (2):CD008544. PMC: 10585425. DOI: 10.1002/14651858.CD008544.pub2. View